Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the uptake of premium priced emerging therapies, including drugs from Shire, Procter & Gamble, Isis Pharmaceuticals, and PDL BioPharma will drive sales in 2015 to $1.1 billion in the market to treat ulcerative colitis.
The new Pharmacor report entitled Ulcerative Colitis also finds that continued use of Centocor/Schering-Plough/Tanabe's Remicade (infliximab) as a treatment for the disease will contribute to sales growth over the next ten years. The acceptance by gastroenterologists of Remicade, currently the only biologic agent approved for the treatment of ulcerative colitis, will foster the emergence of a greater number of targeted biologics to treat the disease in the United States, Japan, France, Germany, Italy, Spain, and the United Kingdom.
"With the exception of the launch of Remicade, there had been virtually no change for several years in therapeutic options or in medical practice for treating ulcerative colitis," said Vickie Lai, analyst at Decision Resources, Inc. "This has caused significant anticipation for the launch of more biologics to treat ulcerative colitis and, because of the premium price of these drugs, they will be a primary driver of sales during the next decade."
About Ulcerative Colitis
Ulcerative colitis is an inflammatory bowel disease characterized by chronic inflammation and ulceration of the mucosal and submucosal layers of the large intestine. Ulcerative colitis afflicts a relatively small portion of the general population but the market to treat the disease represents significant potential for drug developers owing to the high unmet need for effective and safe treatments and to the fact that the disease is a chronic condition that typically requires a lifelong medication regimen.
About Decision Resources
Decision Resources, Inc. (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 email@example.com
SOURCE: Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
Web site: http://www.decisionresources.com/